Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089694 | 1.00 | SIGMAR1 (0.46) | SIGMAR1LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4836946 | 0.82 | SIGMAR1 (0.52) | SIGMAR1LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4292791 | 0.82 | SIGMAR1 (0.52) | SIGMAR1LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4842229 | 0.82 | SIGMAR1 (0.52) | SIGMAR1LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5563432 | 0.82 | SIGMAR1 (0.47) | SIGMAR1LMNAALDH1A1BCHEACHE | |
| SCHEMBL5563430 | 0.82 | SIGMAR1 (0.47) | SIGMAR1LMNAALDH1A1BCHEACHE | |
| SCHEMBL2089277 | 0.81 | SIGMAR1 (0.53) | SIGMAR1LMNAALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL29257059 | 0.80 | SIGMAR1 (0.52) | SIGMAR1LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL7240008 | 0.80 | SIGMAR1 (0.52) | SIGMAR1LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6726679 | 0.76 | SIGMAR1 (0.50) | SIGMAR1LMNAALDH1A1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329908-B2 | Dual action antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2011-03-10 | — | — | US | disclosed |
| US-7820823-B2 | Dual action antibiotics | Morphochem Aktiengesellschaft Fur Kominatorische Chemi (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20050096343-A1 | Dual action antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096343-A1 | Dual action antibiotics | SLC11A2, MRPL21, MAP2K5 | SIGMAR1 1702/4885LMNA 3271/4885ALDH1A1 2592/4885 |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | SLC11A2, MRPL21, MAP2K5 | SIGMAR1 1314/4885LMNA 3185/4885ALDH1A1 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.